12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esbriet pirfenidone regulatory update

InterMune said the Italian Medicines Agency (AIFA) approved the pricing and reimbursement conditions of Esbriet pirfenidone to treat adults with mild to moderate idiopathic pulmonary fibrosis (IPF). Esbriet, which is slated to launch in Italy in the first week of July, will have a gross ex-factory price of €32,994 ($43,978) and will...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >